慢性鼻窦炎伴鼻息肉患者使用2型生物制剂的真实世界不良事件
单机构回顾性研究纳入87例使用度普利尤单抗和51例使用美泊利单抗的慢性鼻窦炎伴鼻息肉患者,两组分别有39例(45%)和10例(20%)发生不良事件,校正比值比为3.8(95%CI,1.5-10.5),两种生物制剂的不良事件谱不同。
要点
- 度普利尤单抗组45%(39例)发生不良事件,美泊利单抗组20%(10例)发生不良事件。
- 度普利尤单抗最常见不良事件为关节痛16%、皮疹14%、结膜炎或干眼症10%。
- 美泊利单抗主要不良事件为头痛6%和乏力6%,7例度普利尤单抗和3例美泊利单抗患者因不良事件停药。
核心结论
- 度普利尤单抗和美泊利单抗具有不同的不良事件谱,本研究有助于为临床医生在慢性鼻窦炎伴鼻息肉患者中使用2型生物制剂的决策提供信息。
研究设计与样本
- 单机构回顾性研究,纳入2016年1月1日至2023年7月1日期间诊断为慢性鼻窦炎伴鼻息肉、至少接受过一次内镜鼻窦手术、且至少使用两剂度普利尤单抗或美泊利单抗的患者,共87例使用度普利尤单抗和51例使用美泊利单抗。
- 收集临床人口学信息和既往病史及手术史,主要结局为不良事件的发生率和类型,采用逻辑回归计算校正比值比比较两种生物制剂,并探讨发生不良事件的危险因素。
主要发现
- 度普利尤单抗组39例(45%)和美泊利单抗组10例(20%)发生不良事件。
- 两组不良事件率的校正比值比为3.8(95%CI,1.5-10.5)。
- 度普利尤单抗最常见不良事件为关节痛(16%)、皮疹(14%)、结膜炎或干眼症(10%)。
- 美泊利单抗主要不良事件为头痛(6%)和乏力(6%)。
- 7例度普利尤单抗患者和3例美泊利单抗患者因不良事件停药;美泊利单抗平均治疗时长22.5个月(范围1-77),度普利尤单抗平均治疗时长15.9个月(范围1-35)。
临床怎么用
- 作者认为本研究有助于为临床医生在慢性鼻窦炎伴鼻息肉患者中使用2型生物制剂的决策提供信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the frequency and nature of adverse events related to type 2 biologic use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), including dupilumab and mepolizumab. METHODS: This is a single-institution retrospective study of real-world patient data. Patients were included if they have a diagnosis of CRSwNP, have undergone at least one endoscopic sinus surgery, and have taken at least two doses of dupilumab or mepolizumab between January 1, 2016, and July 1, 2023. Data collected include clinicodemographic information and past medical/surgical history. The primary outcomes are the incidence and types of adverse events. Adjusted odds ratio was calculated to compare the biologics using logistic regression. Risk factors for developing adverse events were investigated. RESULTS: Eighty-seven patients on dupilumab and 51 patients on mepolizumab were included. Thirty-nine (45%) and 10 (20%) patients respectively encountered adverse events, which differed from phase 3 trial data. The adjusted odds ratio for adverse event rates between these two treatment groups was 3.8 (95% CI, 1.5-10.5). The most common adverse events for dupilumab were arthralgia (16%), rash (14%), and conjunctivitis or xerophthalmia (10%). The main adverse events for mepolizumab were headache (6%) and fatigue (6%). Seven dupilumab and three mepolizumab patients discontinued therapy due to adverse events. The average duration of treatment was 22.5 (range: 1-77) months for mepolizumab and 15.9 (range: 1-35) months for dupilumab. CONCLUSION: Dupilumab and mepolizumab have distinct adverse event profiles. This study contributes to informing clinicians' decisions regarding the use of type 2 biologics in CRSwNP patients. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:3054-3059, 2024.
引用
- Dorling M, Hernaiz-Leonardo JC, Pascual A, et al. Real-World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps. Laryngoscope. 2024. PMID: 38314858. doi:10.1002/lary.31305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。